Free press releases distribution network?

Agency / Source: GenericsWeb Pty Ltd | Ark Patent Intelligence

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



GenericsWeb Analyses Fosaprepitant and its Surrounding Patent Landscape - GenericsWeb.com - Emend (Fosaprepitant) – an attractive opportunity for makers of generics - ArkPatentIntelligence.com
GenericsWeb Analyses Fosaprepitant and its Surrounding Patent Landscape - GenericsWeb.com

 

PRZOOM - /newswire/ - Sydney, New South Wales, Australia, 2010/11/29 - Emend (Fosaprepitant) – an attractive opportunity for makers of generics - ArkPatentIntelligence.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article based on its proprietary patent intelligence for Emend®/Ivemend® (Fosaprepitant), Merck's drug for the prevention of chemotherapy induced nausea and vomiting. The article analyses the surrounding patent landscape, highlighting the need for comprehensive, up-to-date information in the development of launch strategies that minimise the cost of litigation and understanding the barriers to launch as to receive the benefits of your generic product being first to market.

Key findings of the article include:

• In most countries where Emend is marketed, the data and market exclusivity will expire before patent expiry thus will not affect the date of generic competition.

• Patents protecting the use of the type of active ingredient (Neurokinin-1 receptor antagonist) would expire at the latest by July 2013. US patents in this family are currently the subject of litigation in regard to Sandoz’ paragraph IV certified ANDA for Aprepitant (Emend).

• Patents protecting the Fosaprepitant molecule would likely continue to be in force until 2020 (2019 in the US) when patent term extensions or SPCs expire (assuming pending SPC applications are granted).

Fosaprepitant, a selective Neurokinin-1 (NK-1) receptor antagonist and substance P inhibitor is an anti-emetic agent marketed by Merck under the brand name Emend. Available as a powder for injection, Fosaprepitant it is a prodrug of the active ingredient Aprepitant found in the oral dosage form sharing the same brand name. Sales of Emend exceeded US$300 million in 2009 and continue with double digit growth in 2010.

About GenericsWeb – THE SEARCH IS OVER

GenericsWeb (genericsweb.com), the leader in pharmaceutical patent analysis and searching holds an impeccable track record in providing quality patent information, and has allowed numerous pharmaceutical companies to successfully navigate intellectual property hazards. GenericsWeb is headquartered in Sydney, Australia, with offices in North America and Europe. All staff are highly skilled and experienced internationally and have extensive experience in pharmaceutical sciences and patent searching.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GenericsWeb Pty Ltd | Ark Patent Intelligence

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenericsWeb Analyses Fosaprepitant and its Surrounding Patent Landscape - GenericsWeb.com

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Yoann Bretonnet - GenericsWeb.com 
+61(2) 9262 7696 info[.]genericsweb.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenericsWeb Pty Ltd | Ark Patent Intelligence securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GenericsWeb Pty Ltd | Ark Patent Intelligence / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com

Visit  Triggr & Bloom







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today